Antimicrobial resistance emerges as one of the principal public health problems of the century. The pharmaceutical industry faces major challenges, and the development of new drug does not accompany antimicrobial resistance rises. In this context, there is an urgent need for studies addressing the combination of existing drugs in conjunction with new antimicrobial alternatives. We propose to investigate the synergistic activity of bacterial photoinactivation by blue light in combination with chemotherapeutic antimicrobial agents used in the clinical routine. This study will be part of the PhD project titled "Bacterial photoinactivation of mastitis pathogens by blue light: mechanisms of action and cell security - pre-clinical study " funded by FAPESP (PROCESS #2016/25095-2). Will be conducted under the supervision of Prof. Tianhong Dai, PhD, at the Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA, USA. Drug-resistance bacteria belonging to the ESKAPE group (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumanni, Pseudomonas aeruginosa, and Escherichia coli) will be used. The combination will be performed as recommended by CLSI to minimal inhibitory concentration. The interpretation of these results will be complementary to our studies and can indirectly elucidate the structural damage targets promoted by the blue light.
News published in Agência FAPESP Newsletter about the scholarship: